Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
| Autor: | Munehiro Kitada, Ai Takeda-Watanabe, Atsushi Nakagawa, Keizo Kanasaki, Shin-ichi Tsuda, Daisuke Koya, Makoto Nishizawa, Kazunori Konishi, Mizue Fujii |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Renal function 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology albuminuria Nephropathy Diabetic nephropathy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus medicine Pathophysiology/Complications Creatinine business.industry medicine.disease anti-diabetic drugs Endocrinology chemistry Anagliptin Albuminuria nephropathy type 2 diabetes medicine.symptom business medicine.drug |
| Zdroj: | BMJ Open Diabetes Research & Care |
| ISSN: | 2052-4897 |
| Popis: | Objective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy. Methods Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who were switched to anagliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors were analyzed regarding primary and secondary endpoints. The primary endpoint was change in hemoglobin A1c (HbA1c) during treatment with anagliptin. Additionally, we evaluated changes in lipid data (low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglyceride), blood pressure (BP), urinary albumin to creatinine ratio (UACR), liver-type fatty acid-binding protein to creatinine ratio (ULFABP) and renal function (estimated glomerular filtration rate and serum cystatin C) as secondary endpoints. Results After switching to anagliptin from other DPP-4 inhibitors, the levels of HbA1c in the 20 participants showed no significant change, 7.5%±1.2% at 24 weeks compared with 7.3%±0.9% at baseline. The levels of the log10-transformed UACR were significantly reduced from 1.95±0.51 mg/g creatinine (Cr) at baseline to 1.76±0.53 mg/g Cr at 24 weeks after anagliptin treatment (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|